Clinical trial · no report yet · Phase 3
NCT06498479
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
- NCT06498479 ↗
- Completed
- Hansoh BioMedical R&D Company
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- ARTEMIS-008：A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Small Cell Lung Cancer
- Interventions
- HS-20093; Topotecan
- Arms
- HS-20093 · Experimental
- Topotecan · Active comparator
- Enrollment
- 461
- Primary outcomes
- Overall survival
- Sponsor
- Hansoh BioMedical R&D Company
- Start
- Jul 4, 2024
- Primary completion
- Aug 20, 2026
- Results posted
- No
- Registry record
- NCT06498479 · updated Oct 16, 2026